This group also conducted a phase 2 prospective study in patients with AIHA, including 6 patients with ES, and showed that recombinant EPO induced a significant hemoglobin response of 74% in 1 month and 91% at 12 months [11]. This evidence concerns the gene EPO and autoimmune hemolytic anemia.